CWA Asset Management Group LLC purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 14,396 shares of the company's stock, valued at approximately $576,000.
Other institutional investors also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Harmony Biosciences in the second quarter valued at approximately $36,000. CWM LLC boosted its holdings in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company's stock worth $59,000 after acquiring an additional 775 shares during the period. Quarry LP purchased a new stake in shares of Harmony Biosciences in the second quarter worth $62,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock worth $80,000 after purchasing an additional 360 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in Harmony Biosciences by 1,608.1% during the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company's stock valued at $77,000 after buying an additional 2,396 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts have recently issued reports on HRMY shares. Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday, October 10th. UBS Group assumed coverage on Harmony Biosciences in a report on Tuesday, September 10th. They issued a "buy" rating and a $56.00 target price for the company. Raymond James reiterated an "outperform" rating and set a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $52.00 price target on shares of Harmony Biosciences in a report on Tuesday, October 29th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $47.00.
Read Our Latest Research Report on Harmony Biosciences
Insider Activity
In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 30.80% of the company's stock.
Harmony Biosciences Trading Down 2.3 %
HRMY traded down $0.83 during midday trading on Tuesday, hitting $35.08. The company's stock had a trading volume of 711,123 shares, compared to its average volume of 477,868. The firm has a market cap of $2.00 billion, a P/E ratio of 16.71, a PEG ratio of 0.67 and a beta of 0.77. Harmony Biosciences Holdings, Inc. has a 52-week low of $23.42 and a 52-week high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average price of $36.15 and a two-hundred day moving average price of $33.41.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter in the prior year, the business posted $0.63 earnings per share. Harmony Biosciences's revenue for the quarter was up 16.0% on a year-over-year basis. On average, research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current year.
About Harmony Biosciences
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
